Search results for "POINT"

showing 10 items of 4385 documents

Randomized Prospective Study in Patients With Complex Regional Pain Syndrome of the Upper Limb With High-Frequency Spinal Cord Stimulation (10-kHz) a…

2021

Objective The objective of this prospective randomized study of cases and controls was to evaluate the efficacy of treatment with low-frequency spinal cord stimulation (LF-SCS) and 10 kHz spinal cord stimulation (10-kHz SCS) in patients diagnosed with complex regional pain syndrome type I (CRPS) with upper limb involvement. Materials and methods Fifty patients were randomized to receive conventional treatment or SCS with a commercially available low-frequency or 10-kHz system. Patients were assessed at 1, 3, 6, and 12 months. The primary endpoint was at 12-months post permanent implantation of the SCS devices. Outcome measures assessed included: Numerical Rating Scale (NRS), 12-Item Short-F…

medicine.medical_specialtyUpper Extremity03 medical and health sciences0302 clinical medicineRating scalemedicineClinical endpointHumansProspective StudiesProspective cohort studyPain MeasurementSpinal Cord Stimulationintegumentary systembusiness.industryMinimal clinically important differenceGeneral Medicinemedicine.diseaseNeuromodulation (medicine)Oswestry Disability IndexAnesthesiology and Pain Medicinemedicine.anatomical_structureComplex regional pain syndromeTreatment OutcomeNeurologySpinal CordPhysical therapyUpper limbNeurology (clinical)Chronic Painbusiness030217 neurology & neurosurgeryComplex Regional Pain SyndromesNeuromodulation : journal of the International Neuromodulation SocietyREFERENCES
researchProduct

Interocular differences in visual quality due to ocular aberrations and scattering in a patient with post-traumatic anisocoria: A case report

2012

AbstractA 41-year-old patient with visual disturbances after an ocular trauma in right eye three years before was carefully analyzed and discussed. No corneal or intraocular sequelae were present. Only a significant anisocoria could be observed. Right eye (RE) achieved a best spectacle-corrected visual acuity (BSCVA) of 0.05 LogMAR with a refraction of +0.50 sphere and −1.25 cylinder. Left eye (LE) achieved a BSCVA of 0.0 LogMAR with a refraction of +0.75 sphere and −1.00 cylinder. In photopic conditions pupil diameter was 4.96mm for RE and 3.02mm for LE whereas in scotopic conditions, these values were 7.45mm and 6.71mm, respectively. More significant levels of higher-order corneal and ocu…

medicine.medical_specialtyVisual acuitygenetic structuresCase ReportPupilScatteringlcsh:OphthalmologyOphthalmologymedicinelcsh:QC350-467AberraciónScotopic visionPupilaAnisocoriabusiness.industryFunción de dispersión del puntoPupil sizePupilRefractionAnisocoriaPoint spread functioneye diseasesDispersiónlcsh:RE1-994Visual DisturbanceOptometrysense organsmedicine.symptombusinessAberrationlcsh:Optics. LightPhotopic visionOptometryJournal of Optometry
researchProduct

Objectifying acupuncture effects by lung function and numeric rating scale in patients undergoing heart surgery.

2012

Rationale. Poststernotomy pain and impaired breathing are common clinical problems in early postoperative care following heart surgery. Insufficiently treated pain increases the risk of pulmonary complications. High-dose opioids are used for pain management, but they may cause side effects such as respiratory depression.Study Design. We performed a prospective, randomized, controlled, observer-blinded, three-armed clinical trial with 100 patients. Group 1 (n=33) and Group 2 (n=34) received one 20 min session of standardized acupuncture treatment with two different sets of acupoints. Group 3 (n=33) served as standard analgesia control without additional intervention. Results. Primary endpoin…

medicine.medical_specialtyVital capacityArticle Subjectbusiness.industryAnalgesiclcsh:Other systems of medicinelcsh:RZ201-999Pulmonary function testingSurgeryClinical trialFEV1/FVC ratioComplementary and alternative medicineStatistical significanceAcupuncturemedicineClinical endpointbusinessResearch ArticleEvidence-based complementary and alternative medicine : eCAM
researchProduct

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.

2021

The development of mepolizumab, an anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma, is an example of a clinical development program that evolved over time based on sound, basic scientific principles. Initial clinical data on the effects of mepolizumab on lung function in a general asthmatic population were disappointing. However, it became clear that mepolizumab may be more effective against other clinical endpoints, particularly asthma exacerbations, in patients with more severe disease. Furthermore, a developing understanding of asthma disease pathobiology led to the identification of an appropriate target population and predictive biomarker for mepolizumab t…

medicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationDiseaseAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineClinical endpointImmunology and AllergyMedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPrecision MedicineIntensive care medicineAdverse effecteducationComputingMilieux_MISCELLANEOUSAsthmaeducation.field_of_studybusiness.industrymedicine.diseaseAsthmaEosinophils030228 respiratory systemAsthma Control QuestionnairePersonalized medicinebusinessMepolizumabmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Re…

2016

Abstract Background: Management of anemia is a common therapeutic challenge in patients with MDS. Luspatercept (ACE-536), a fusion protein containing modified activin receptor type IIB, is being developed for treatment of anemia in lower-risk MDS. Luspatercept binds GDF11 and other TGF-β superfamily ligands to promote late-stage erythroid differentiation and increase hemoglobin (Hgb) levels (Suragani R, Nat Med, 2014 and Attie K, Am J Hematol, 2014). Aims: This is an ongoing, phase 2, multicenter, open-label, long-term extension study to evaluate the effects of luspatercept in patients (pts) with low-intermediate risk MDS. Endpoints include long-term safety and tolerability, erythroid respo…

medicine.medical_specialtybusiness.industryAnemiaSurrogate endpointMyelodysplastic syndromesImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologySurgery03 medical and health sciences0302 clinical medicineTolerability030220 oncology & carcinogenesisPharmacodynamicsInternal medicineMedicinebusinessAdverse effect030215 immunologyLenalidomidemedicine.drugBlood
researchProduct

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

2016

Abstract Introduction: Temsr (Torisel®) administered at 175 mg IV once weekly for first 3 weeks, followed by 75mg IV once weekly (Temsr 175/75 mg) is approved in the European Union for the treatment of adult patients with relapsed and/or refractory MCL based on an overall positive benefit-risk relationship demonstrated for this treatment regimen in the pivotal phase III study (Hess et al. J Clin Oncol. 2009;27:3822-9). This ongoing phase 4, multicenter, randomized, open-label study was conducted to explore whether similar efficacy can be achieved for the treatment of patients with relapsed/refractory MCL with a Temsr regimen that is expected to yield fewer side effects than the Temsr 175/75…

medicine.medical_specialtybusiness.industryImmunologyEcchymosisHazard ratioCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologySurgeryRegimenRefractoryInternal medicinemedicineClinical endpointmedia_common.cataloged_instanceMantle cell lymphomamedicine.symptomEuropean unionbusinessmedia_commonBlood
researchProduct

VI: Konfidenzintervalle - die Alternative zum p-Wert

2003

Confidence intervals combine the ideas of clinical relevance and statistical significance by using one instructive expression, which enables remarkable reduction of table structures and result sections in scientific publications. Confidence interval based conclusions can be transferred from a clinical trial to its underlying study population with respect to a residual statistical error probability, i.e. the significance concept is retained. However, their presentation using the original unit of the clinical endpoint under consideration allows for immediate interpretation of the results' clinical impact. For example, the comparison of two therapy groups based on a binary endpoint becomes fea…

medicine.medical_specialtybusiness.industryInterval (mathematics)Confidence intervalSurgeryClinical trialOphthalmologyRisk EstimateStatistical significanceRelative riskStatisticsClinical endpointMedicineClinical significancebusinessKlinische Monatsblätter für Augenheilkunde
researchProduct

Late Breaking Abstract - Predictive value of FeNO in patients with non-specific respiratory symptoms: a randomised controlled trial

2017

Background: Fractional exhaled nitric oxide (FeNO) can predict treatment response in asthma, but little is known of its utility in patients with non-specific respiratory symptoms (NSRS). Aims and objectives: To evaluate the association between baseline FeNO and response to treatment with inhaled corticosteroids (ICS) in patients with NSRS. Methods: This was a multi-centre randomised, placebo-controlled trial, carried out in UK and Singapore. It consisted of a 2-week assessment period to establish baseline measurements and a 4-week treatment period with either extrafine ICS (200 µ beclomethasone bid) or placebo. NIOX VERO (Circassia) was used to measure baseline FeNO. The primary endpoint wa…

medicine.medical_specialtybusiness.industryPlacebomedicine.diseaseConfidence intervallaw.inventionRandomized controlled triallawAsthma Control QuestionnaireInternal medicineExhaled nitric oxidemedicineClinical endpointRespiratory systembusinessAsthmaGeneral Practice and Primary Care
researchProduct

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis w…

2019

Background: The gain-of function mutation KIT D816V plays a central role in the pathogenesis of systemic mastocytosis (SM). Among subtypes of SM, indolent SM (ISM) is the most frequent and is associated with normal/near-normal life expectancy; smoldering SM (SSM) is a subtype with a relatively higher burden of mast cells and may be associated with an increased risk of progression to advanced mastocytosis. However, both ISM and SSM patients may experience severe symptoms associated with mast cell mediator release, such as pruritus, diarrhea, anaphylaxis, and bone pain, which can be severely debilitating and have a profoundly negative impact on quality of life. Symptomatic treatments (eg, ant…

medicine.medical_specialtybusiness.industrySurrogate endpointImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseasePlaceboBiochemistryDouble blindInternal medicineMedicineIn patientSystemic mastocytosismedicine.symptombusinessBone painAsthmaBlood
researchProduct